Campaign Targets Biopharmaceutical and Government Potential Out-Licensing Opportunities
SAN DIEGO and COLUMBUS, Ohio, July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and development organization, today announced the launch of their formal marketing campaign, "Less is More," for Zogenix's DosePro® drug delivery technology. The companies previously announced a collaborative agreement to advance out-licensing opportunities of DosePro®, with a focus on co-marketing the technology to potential biopharmaceutical and government clients.
The goal of the campaign is to emphasize the simplicity and benefits of the DosePro technology and its ability to provide instantaneous, needle-free, subcutaneous drug delivery. The first phase of the DosePro marketing campaign was launched at the 2012 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, and featured an exhibition booth and poster advertisements showcasing the technology's new messaging, "Less is More."
The companies completed the roll out of the marketing campaign with the launch of www.DosePro.com and the continued direct-to-client marketing strategies by Battelle. The new DosePro website features video on the needle-free delivery technology, additional information including system specifications, and recent presentations on the DosePro technology given at conferences across the United States.
John Turanin, Vice President and General Manager, DosePro Technology, at Zogenix, commented, "The pharmaceutical industry pipeline includes hundreds of potentially life-changing injectable drugs, mostly biologics. Safety and efficacy are no longer the exclusive determinants for adoption of therapy and competitive advantage. We believe that highly differentiated, patient-preferred alternatives will make a significant difference, and DosePro stands alone with instantaneous, needle-free prefilled dose delivery. Our new DosePro co-marketing campaign with Battelle will help pharmaceutical decision-makers understand these advantages, including DosePro's ability to deliver highly viscous formulations."
Barbara Kunz, President of Battelle Health and Life Sciences, said, "The launch of the DosePro co-marketing campaign allows us to highlight its innovative needle-free delivery technology to biopharmaceutical companies that could potentially benefit from incorporating the technology into their drug development programs. We believe DosePro can address many challenges our customers face today, including the development of differentiated and innovative products and the extension of product life cycles. With our integrated expertise in medical device development and formulation, Battelle can also apply this technology to deliver highly viscous formulations for a variety of biologics."
Battelle's business development professionals responsible for health and life sciences will continue to market DosePro to their clients in strategic product planning meetings, at future conferences, in trade publications, and through other marketing communications. For more information on licensing opportunities using the DosePro platform contact Battelle at 1-800-201-2011 or email@example.com.
The DosePro system is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of sterile liquid drug, subcutaneously, without a needle. The platform is currently used by Zogenix's first commercial product, SUMAVEL DosePro®, and its investigational candidate, ReldayTM. The Company believes that DosePro offers several benefits to patients compared to other subcutaneous needle-based delivery methods, and that it has the potential to become a preferred delivery option for patients and physicians. These benefits include less anxiety or fear due to the lack of a needle, easier disposal without the need for a sharps container, no risk of needle stick injury or contamination, an easy-to-use three step administration process, no need to fill the device prior to use, reliable performance, discreet use and portability. In several clinical trials and market research studies, DosePro has been shown to be preferred by patients over conventional needle-based systems.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ (hydrocodone bitartrate) is an oral, single-entity (without acetaminophen), novel extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In July 2012, the FDA accepted for review a New Drug Application for Zohydro. Zogenix's second DosePro investigational product candidate, Relday, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA an Investigational New Drug Application for Relday.
For additional information, please visit www.zogenix.com.
As the world's largest independent research and development organization, Battelle provides innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.5 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 22,000 employees in more than 130 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy, the U.S. Department of Homeland Security, and a nuclear energy lab in the United Kingdom.
Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact, and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.
Forward Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the marketing campaign's ability to result in an out-license the DosePro technology and the ability of DosePro to address the a challenges of developing differentiated and innovative products and to deliver viscous drug formulations. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: difficulties in identifying, negotiating, executing and carrying out strategic transactions relating to DosePro and obtaining regulatory approval for other DosePro products; risks associated with the development of a larger volume, second generation version of the DosePro technology to accommodate drug formulation volumes greater than 0.5 mL; and the scope, validity and duration of patent protection and other intellectual property rights for DosePro; and other risks described in the company's prior press releases and filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of Zogenix, Inc.
CONTACT: Zogenix Investor Contact
The Ruth GroupZack Kubow
646.536.7020 | firstname.lastname@example.org
Zogenix Media Contact
The Ruth GroupVictoria Aguiar
646.536.7013 | email@example.com
614.424.7208 | firstname.lastname@example.org
614.424.5544 | email@example.comZogenix